Serotonin transporter gene (5-HTT LPR) polymorphism and efficacy of selective serotonin reuptake inhibitors - do we have sufficient evidence for clinical practice

Acta Clinica Croatica

Volumn 52, Issue 3, 2013, Pages 353-362

  Karlović, Dalibor ^a   Serretti, Alessandro ^b  

^a SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Pharmacogenetics; Selective serotonin reuptake inhibitors; Serotonin transporter gene polymorphism

Indexed keywords

SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR;

ADVERSE OUTCOME; CLINICAL PRACTICE; COST; DEPRESSION; DNA POLYMORPHISM; DRUG EFFICACY; ETHNIC GROUP; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRESCRIPTION; REVIEW;

DEPRESSIVE DISORDER; HUMANS; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 84895822855     PISSN: 03539466     EISSN: 13339451     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. M urra y CJ, Lopez AD. Evidence-based health policy: lessons from the Global Burden of Disease Study. Science 1996;274:740-3.
2. Ustun TB , Ayuso-Ma teos JL, Cha tterj i S, Ma thers C, Murra y CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:393- 403.
3. Ma thers CD, Vos ET, Stevenson CE, Begg SJ. The Australian Burden of Disease Study: measuring the loss of health from diseases, injuries and risk factors. Med J Aust 2000;172:592-6.
4. Wittchen HU, Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357-76.
5. Stahl SM. Basic psychopharmacology of antidepressants. Part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59(Suppl 4):5-14.
6. Stahl SM. Stahl's essential psychopharmacology, 3rd ed. Cambridge: CambridgeUniversity Press, 2008.
7. M iddlemiss DN, Pr ice GW, Wa tson JM. Serotonergic targets in depression. Curr Opin Pharmacol 2002;2:18-22.
8. M oncr ieff J, Kirsch I. Efficacy of antidepressants in adults. BMJ 2005;331:551-7.
9. Masa nd PS. Tolerability and adherence issues in antidepressant therapy. Clin Ther 2003;25:2289-304.
10. Serr etti A, Chiesa A, Cala ti R, Perna G, Bell odi L, De Ronch i D. Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol 2009;24:1-18.
11. Serr etti A, Cala ti R, Oas i O, De Ronch i D, Colombo C. Dissecting the determinants of depressive disorders outcome: an in depth analysis of two clinical cases. Ann Gen Psychiatry 2007;6:5.
12. N ierenberg AA. Predictors of response to antidepressants general principles and clinical implications. Psychiatr Clin North Am 2003;26:345-52.
13. Hors tmann S, Binder EB . Pharmacogenomics of antidepressant drugs. Pharmacol Ther 2009;124:57-73.
14. Porcell i S, Fa bbri C, Spina E, Serr etti A, De Ronch i D. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol 2011;7:1101-15.
15. Crisa full i C, Fa bbri C, Porc ell i S, Dra go A, Spina E, De Ronch i D, Serr etti A. Pharmacogenetics of antidepressants. Front Pharmacol 2011;2:1-21.
16. Crnkovic D, Bulja n D, Karl ovic D, Kr mek M. Connection between inflammatory markers, antidepressants and depression. Acta Clin Croat 2012 Mar;51:25-33.
17. Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch KP . Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-4.
18. O gilvie AD, Ba tters by S, Bubb VJ, Fink G, Har mar AJ, Goodwin GM, Smith CAD. Polymorphism of serotonin transporter gene associated with susceptibility to major depression. Lancet 1996;347:731-3.
19. Lesch KP, Bengel D, Heils A, Sabol SZ, Gr eenberg BD, Petri S, Benja min J, Müller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274:1527-31.
20. G oldman N, Gl ei DA, Lin YH, Weinstein M. The serotonin transporter polymorphism (5-HTT LPR): allelic variation and links with depressive symptoms. Depress Anxiety 2010;27:260-9.
21. Kunugi H, Hattori M, Ka to T, Ta tsumi M, Sakai T, Sasa ki T, Hirose T, Na nko S. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997;2:457-62.
22. Ka to M, Serr etti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010;15:473-500.
23. Smeral di E, Zanar di R, Benedetti F, Di Bella D, Perez J, Catala no M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998;3:508-11.
24. Zanar di R, Serr etti A, Ross ini D, Fra nch ini L, Cusin C, Lattuada E, Dotoli D, Smeral di E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTT LPR in delusional and nondelusional depression. Biol Psychiatry 2001;50:323-30.
25. Zanar di R, Benedetti F, Di Bella D, Catala - no M, Smeral di E. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000;20:105-7.
26. P oll ock BG, Ferr ell RE, Mulsa nt BH, Ma - zumdar S, Mill er M, Sweet RA, Da vis S, Kirsh ner MA, Houck PR, Stac k JA, Reynolds CF, Kupfer DJ. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in latelife depression. Neuropsychopharmacology 2000;23:587-90.
27. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Mill er AL, Rogers GR, Kennedy MA. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003;6:339-46.
28. Arias B, Catala n R, Gas to C, Gutiérr ez B, Fa ñanás L. 5-HTT LPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-week followup study. J Clin Psychopharmacol 2003;23:563-7.
29. P erl is RH, Misch oulon D, Smoll er JW, Wan YJ, Lamon-Fa va S, Lin KM, Rosenbaum JF, Fa va M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003,54:879-83.
30. Durha m LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTT LPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004;174:525-9.
31. Serr etti A, Cusin C, Ross ini D, Artioli P, Dotoli D, Zanar di R. Further evidence of a combined effect of SERTP R and TP H on SSRIs response in mood disorders. Am J Med Genet B Neuropsychiatr Genet 2004;129:36-40.
32. Smits KM, Smits LJ, Sch outen JS, Stelma FF, Nelemans P, Pr ins MH. Influence of SERTP R and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004;9:433-41.
33. K irchh einer J, Nickch en K, Sass e J, Bauer M, Roots I, Br ockmöll er J. A 40-basepair VNT R polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenomics J 2006;7:48-55.
34. B ozina N, Peles AM, Sagud M, Bilusic H, Jakovlj evic M. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. World J Biol Psychiatry 2008;3:190-7.
35. D ogan O, Yuksel N, Er gun MA, Yilmaz A, Ilha n MN, Karsl ioglu HE, Koc A, Menevse A. Serotonin transporter gene polymorphisms and sertraline response in major depression patients. Genet Test 2008;12:225- 31.
36. Huezo-Diaz P,Uh er R, Smith R, Rietsch el M, Henigsberg N, Marusic A, Mors O, Ma ier W, Hauser J, Souery D, Plac entino A, Zobel A, Lars en ER, Czers ki PM, Gupta B, Hoda F, Perr oud N, Far mer A, Cra ig I, Aitch ison KJ, McGuffin P. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009;195:30-8.
37. Mar on E, Ta mmiste A, Kallassalu K, Ell er T, Vasar V, Nutt DJ, Metspalu A. Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression. Eur Neuropsychopharmacol 2009;19:451-6.
38. Mraz ek DA, Rush AJ, Biernac ka JM, O'ka ne DJ, Cunningha m JM, Wieben ED, Scha id DJ, Dr ews MS, Cours on VL, Snyder KA, Blac k JL 3rd, Weinsh ilboum RM. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2009;150B:341-51.
39. Ill i A, Poutanen O, Setälä-Soikkeli E, Ka mpman O, Viikki M, Huhtala H, Mononen N, Haraldss on S, Koivisto PA, Leinonen E, Lehtimäki T. Is 5-HTT LPR linked to the response of selective serotonin reuptake inhibitors in MDD ? Eur Arch Psychiatry Clin Neurosci 2010;261:95-102.
40. Kra ft JB, Peters EJ, Sla ger SL, Jenkins GD, Reinal da MS, McGra th PJ, Hamilton SP. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007;61:734-42.
41. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendar kar N, Hobby HM, Ga napathy V, Leibach FH. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002;51:723-32.
42. Murphy GM Jr, Holla nder SB, Rodrigues HE, Kr emer C, Scha tzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-9.
43. P eters EJ, Sla ger SL, McGra th PJ, Knowles JA, Hamilton SP. Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004;9:879-89.
44. Kra ft JB, Sla ger SL, McGra th PJ, Hamilton SP. Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005;58:374-81.
45. N g CH, Eas teal S, Ta n S, Sch weitzer I, Ho BK, Aziz S. Serotonin transporter polymorphisms and clinical response to sertraline across ethnicities. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:953-7.
46. Hu XZ, Rush AJ, Char ney D, Wils on AF, Sora nt AJ, Papanicola ou GJ, Fa va M, Trivedi MH, Wisniewski SR, Laj e G, Pa ddock S, McMah on FJ, Ma nji H, Lipsky RH. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007;64:783-92.
47. Ruhe HG, Ooteman W, Booij J, Mich el MC, Moeton M, Baas F, Sch ene AH. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenet Genomics 2009;19:67-76.
48. Reimherr F, Amsterdam J, Dunner D, Adler L, Zha ng S, Will iams D, Marcha nt B, Mich els on D, Nierenberg A, Scha tzberg A, Feldman P. Genetic polymorphisms in the treatment of depression: speculations from an augmentation studyusing atomoxetine. Psychiatry Res 2010;175:67-73.
49. K im DK, Lim SW, Lee S, Sohn SE, Kim S, Hah n CG, Carr oll BJ. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000;11:215-9.
50. Y osh ida K, Ito K, Sato K, Ta kahash i H, Ka - mata M, Higuch i H, Shimizu T, Itoh K, Inoue K, Tezuka T, Suzuki T, Oh kubo T, Sugawara K, Otani K. Influence of the serotonin transporter genelinked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-6.
51. Yu YW, Tsa i SJ, Chen TJ, Lin CH, Hong CJ. Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002;7:1115-9.
52. Ta kahash i H, Yosh ida K, Ito K, Sato K, Ka - mata M, Higuch i H, Shimizu T, Ito K, Inoue K, Tezuka T, Suzuki T, Oh kubo T, Sugawara K. No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment. Eur Neuropsychopharmacol 2002;12:477-81.
53. Hong CJ, Chen TJ, Yu YW, Tsa i SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006;6:27-33.
54. Ka to M, Fukuda T, Wa keno M, Fukuda K, Okugawa G, Ikenaga Y, Ya mash ita M, Ta kekita Y, Nobuhara K, Azuma J, Kinosh ita T. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006;53.186-95.
55. K im H, Lim SW, Kim S, Kim JW, Cha ng YH, Car - roll BJ, Kim DK. Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. Jama 2006;296:1609-18.
56. U mene-Na kano W, Yosh imura R,Ueda N, Suzuki A, Ikenouch i-Sugita A, Hori H, Otani K, Nakamura J. Predictive factors for responding to sertraline treatment: views from plasma catecholamine metabolites and serotonin transporter polymorphism. J Psychopharmacol 2009;24:1764-71.
57. Y osh imura R,Umene-Na kano W, Suzuki A,Ueda N, Miyamoto K, Ikenouch i-Sugita A, Hori H, Otani K, Na kamura J. Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Hum Psychopharmacol 2009;24:489-94.
58. Serr etti A, Ka to M, De Ronch i D, Kinosh ita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTT LPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007b;12:247-57.
59. Porcell i S, Fa bbri C, Serr etti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTT LPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012. (in press)
60. Taylor MJ, Sen S, Bha gwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 2010;68:536-43.
61. Porcelli S, Fabbi C, Drago A, Gibiino S, De Ronchi D, Serretti A. Genetics and antidepressant: where we are. Clin Neuropsychiatry 2011;8:99-150.
62. Hu X, Orosz i G, Chun J, Smith TL, Goldman D, Schuckit MA. An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk. Alcohol Clin Exp Res 2005;29:8-16.
63. Serretti A, Calati R, Mandelli L, De Ronchi D. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 2006;7:1659-69.
64. Mandelli L, Serretti A, Zanardi R, Rossini D, De Ronchi D, Tarricone I, Colombo C. Antidepressant response in the elderly. Psychiatry Res 2007;152:37-44.
65. Gressier F, Bouaziz E, Verstuyft C, Hardy P, Becquemont L, Corruble E. 5-HTT LPR modulates antidepressant efficacy in depressed women. Psychiatr Genet 2009;19:195-200.
66. Grigoriadis S, Robinson GE . Gender issues in depression. Ann Clin Psychiatry 2007;19:247-55.
67. Baffa A, Hohoff C, Baune BT , Müller-Tidow C, Tidow N, Freitag C, Zwanzger P, Deckert J, Arolt V, Domsch ke K. Norepinephrine and serotonin transporter genes: impact on treatment response in depression. Neuropsychobiology 2010;62:121-31.
68. Willeit M, Praschak-Rieder N, Neumeister A, Zill P, Leisch F, Stastny J, Hilger E, Thierry N, Konstantinidis A, Winkler D, Fuchs K, Sieghart W, Aschauer H, Ackenheil M, Bondy B, Kasper S. A polymorphism (5-HTT LPR) in the serotonin transporter promoter gene is associated with DSM-IV depression subtypes in seasonal affective disorder. Mol Psychiatry 2003;8:942-6.
69. Schinka JA, Busch RM, Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTT LPR) and trait anxiety. Mol Psychiatry 2004;9:197-202.
70. Oligati P, Bajo E, Bigell i M, De Ronchi D, Serretti A. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in highand middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry 2012;36:147-54.
71. Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry 2011;12:501-15.
72. Serretti A, Artioli P. Ethical problems in pharmacogenetic studies of psychiatric disorders. Pharmacogenomics J 2006;6:289-95.